AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12861344 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (60 ml) placebo infusion
Number of subjects: 12
Study 11060526 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin G (IVIgG), 1 g/kg body weight, given on days 0, 3, 7, 14, and 21
Number of subjects: 81
Study 11060526 — intervention group
Group type: COMPARATOR
Intervention: Placebo (albumin)
Number of subjects: 81
Study 11060526 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (comparison group with IgG levels >4 g/L)
Number of subjects: 81
Study 9863128 — intervention group
Group type: EXPERIMENTAL
Intervention: Sini decoction (n = 23)
Number of subjects: 46
Study 9863128 — intervention group
Group type: COMPARATOR
Intervention: PTCA only (n = 23)
Number of subjects: 46
Study 8307341 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation-based stress reduction program
Number of subjects: 77
Study 3520708 — intervention group
Group type: EXPERIMENTAL
Intervention: B-15000 (new non-ionic contrast medium)
Number of subjects: 0
Study 3520708 — intervention group
Group type: COMPARATOR
Intervention: Isteropac (traditional ionic contrast medium)
Number of subjects: 0
Study 29725191 — intervention group
Group type: EXPERIMENTAL
Intervention: SISTAS intervention (12 weekly classes followed by nine monthly booster sessions)
Number of subjects: 337
Study 27244210 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone from the iliac crest region (n=4)
Number of subjects: 12
Study 27244210 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human bone morphogenetic protein-2 (rhBMP-2) (n=8)
Number of subjects: 12
Study 24931702 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 1345
Study 24931702 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM-1
Number of subjects: 1345
Study 24931702 — intervention group
Group type: EXPERIMENTAL
Intervention: sVCAM-1
Number of subjects: 1345
Study 24931702 — intervention group
Group type: EXPERIMENTAL
Intervention: Models including novel biomarkers
Number of subjects: 1345
Study 22673035 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (n=17), 12 sessions of 40 minutes each, three days/week for four weeks.
Number of subjects: 34
Study 22673035 — intervention group
Group type: COMPARATOR
Intervention: Physical Therapy (n=17), 12 sessions of 40 minutes each, three days/week for four weeks.
Number of subjects: 34
Study 20206581 — intervention group
Group type: EXPERIMENTAL
Intervention: sTMS (single-pulse transcranial magnetic stimulation)
Number of subjects: 201
Study 20206581 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 201
Study 20206581 — intervention group
Group type: COMPARATOR
Intervention: sTMS and Sham stimulation
Number of subjects: 201
Study 18793543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C formula (GFR = 90.63 x cystatin C‐1.192)
Number of subjects: 592
Study 18793543 — intervention group
Group type: COMPARATOR
Intervention: MDRD formula
Number of subjects: 592
Study 18793543 — intervention group
Group type: COMPARATOR
Intervention: CG formula
Number of subjects: 592
Study 16241919 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment and regular monitoring (Group B)
Number of subjects: 300
Study 16241919 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard management (Group A)
Number of subjects: 300
Study 16241919 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 300
Study 12362930 — intervention group
Group type: EXPERIMENTAL
Intervention: Riamet (artemether-lumefantrine)
Number of subjects: 42
Study 12362930 — intervention group
Group type: COMPARATOR
Intervention: Quinine (10 mg/kg body weight, intravenous infusion)
Number of subjects: 42
Study 12362930 — intervention group
Group type: EXPERIMENTAL
Intervention: Riamet + Quinine
Number of subjects: 42
Study 10102765 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 20
Study 10102765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7587918 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple insulin injection treatment (MIT) group
Number of subjects: 110
Study 7587918 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin injection treatment (CIT) group
Number of subjects: 110
Study 1971955 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 or 30 mg flurazepam
Number of subjects: 80
Study 1971955 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 or 0.50 mg triazolam
Number of subjects: 80
Study 1971955 — intervention group
Group type: COMPARATOR
Intervention: Placebo at bedtime
Number of subjects: 80
Study 1971955 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg caffeine
Number of subjects: 80
Study 1971955 — intervention group
Group type: COMPARATOR
Intervention: Placebo in the morning
Number of subjects: 80
Study 922640 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha feedback
Number of subjects: 75
Study 922640 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG feedback
Number of subjects: 75
Study 922640 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha, EMG, or joked feedback
Number of subjects: 75
Study 922640 — intervention group
Group type: COMPARATOR
Intervention: No-feedback or no-treatment
Number of subjects: 75
Study 922640 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 75
Study 30879734 — intervention group
Group type: EXPERIMENTAL
Intervention: Late initiation of supplemental parenteral nutrition (PN) after one week
Number of subjects: 1440
Study 30879734 — intervention group
Group type: COMPARATOR
Intervention: Early initiation of supplemental parenteral nutrition (PN) within 24 hours
Number of subjects: 1440
Study 30879734 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Z‐score increase
Number of subjects: 1440
Study 31711543 — intervention group
Group type: EXPERIMENTAL
Intervention: Free text analysis using the Freetext Matching Algorithm
Number of subjects: 3800
Study 27964826 — intervention group
Group type: EXPERIMENTAL
Intervention: UC-MSC treatment (1.0 × 10^6 MSCs per kg body weight, six doses through peripheral intravenous infusion)
Number of subjects: 12
Study 27964826 — intervention group
Group type: EXPERIMENTAL
Intervention: UC-MSC treatment
Number of subjects: 12
Study 27964826 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapeutic protocol (control group)
Number of subjects: 12
Study 25244977 — intervention group
Group type: EXPERIMENTAL
Intervention: ESwab
Number of subjects: 80
Study 25244977 — intervention group
Group type: COMPARATOR
Intervention: Multi-sample method
Number of subjects: 80
Study 23279308 — intervention group
Group type: EXPERIMENTAL
Intervention: Text plus a visual image of predicted internal body fat (image arm)
Number of subjects: 901
Study 23279308 — intervention group
Group type: COMPARATOR
Intervention: Solely text form (control arm)
Number of subjects: 901
Study 21771279 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based psychological treatment program (Revive) consisting of communication skills training, sensate focus exercises, and regular contact with a therapist
Number of subjects: 39
Study 21771279 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 39
Study 18453491 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 120
Study 18453491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 16534755 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-DTPA-DeA at 2.5 micromol/kg
Number of subjects: 113
Study 16534755 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-DTPA-DeA at 5.0 micromol/kg
Number of subjects: 113
Study 16534755 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-DTPA-DeA at 7.5 micromol/kg
Number of subjects: 113
Study 16534755 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-DTPA-DeA (all doses)
Number of subjects: 113
Study 14635462 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with a grass extract (ALK‐Abellò)
Number of subjects: 22
Study 14635462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 11037741 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 766
Study 11037741 — intervention group
Group type: COMPARATOR
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 766
Study 11037741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 766
Study 8957141 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced day treatment program plus abstinent contingent work therapy and housing (EC)
Number of subjects: 176
Study 8957141 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 176
Study 1568426 — intervention group
Group type: COMPARATOR
Intervention: 10 mg quinapril (single dose)
Number of subjects: 16
Study 1568426 — intervention group
Group type: COMPARATOR
Intervention: 10 mg quinapril twice daily for 14 days
Number of subjects: 16
Study 3894337 — intervention group
Group type: EXPERIMENTAL
Intervention: Molindone (injection for 2-3 days, then oral for up to 4 weeks)
Number of subjects: 35
Study 3894337 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (injection for 2-3 days, then oral for up to 4 weeks)
Number of subjects: 35
Study 3894337 — intervention group
Group type: COMPARATOR
Intervention: Both drugs (Molindone and Haloperidol)
Number of subjects: 35
Study 30209956 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-FSE-Cube-Flex MRD
Number of subjects: 21
Study 30209956 — intervention group
Group type: COMPARATOR
Intervention: 3D-FSE-Cube
Number of subjects: 21
Study 30268156 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell intradermal vaccinations (two courses of four daily doses)
Number of subjects: 19
Study 30268156 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 19
Study 27352491 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique insertion therapy at anatomical points
Number of subjects: 80
Study 27352491 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture with perpendicular insertion
Number of subjects: 80
Study 24212124 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐month exercise intervention (160 min·wk of moderate‐intensity aerobic walking, twice weekly resistance training with resistance bands)
Number of subjects: 46
Study 24212124 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐month exercise intervention
Number of subjects: 46
Study 22950925 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (exposed to video, audio, and print advertisements promoting parent-child communication about delaying sexual activity)
Number of subjects: 1969
Study 22950925 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to the treatment messages)
Number of subjects: 1969
Study 20230859 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose administration (dose not specified)
Number of subjects: 0
Study 20230859 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task performance (specifics not provided)
Number of subjects: 0
Study 20230859 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose administration (regardless of dose or dual-task conditions)
Number of subjects: 0
Study 16832224 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentive ($100 for 15% reduction in LDL-C)
Number of subjects: 171
Study 16832224 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary educational program
Number of subjects: 171
Study 16832224 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 171
Study 12721177 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10831772 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 259
Study 10831772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 9203099 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (smoother surface with Ra ≤ 0.088 microns and Rz ≤ 1.027 microns)
Number of subjects: 8
Study 9203099 — intervention group
Group type: COMPARATOR
Intervention: Group B (rougher surface)
Number of subjects: 8
Study 9203099 — intervention group
Group type: COMPARATOR
Intervention: Group C (roughest surface)
Number of subjects: 8
Study 8466238 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised budesonide suspension
Number of subjects: 36
Study 3535714 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 30
Study 3535714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30695078 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone app providing ACH antibiotic guidelines
Number of subjects: 436
Study 29459120 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar core stabilization exercise (LCSE)
Number of subjects: 24
Study 29459120 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition (passive cycling in crook lying)
Number of subjects: 24
Study 29459120 — intervention group
Group type: COMPARATOR
Intervention: Control condition (positioning in crook lying and rest)
Number of subjects: 24
Study 29459120 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 24
Study 26929085 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 38
Study 26929085 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 24216616 — intervention group
Group type: EXPERIMENTAL
Intervention: fampridine-SR 25 mg twice daily
Number of subjects: 415
Study 24216616 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 415
Study 21882176 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin 25 mg orally 5 days per week
Number of subjects: 70
Study 21882176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 21882176 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin
Number of subjects: 70
Study 20423422 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training programme
Number of subjects: 121
Study 20423422 — intervention group
Group type: COMPARATOR
Intervention: Attention-control intervention
Number of subjects: 121
Study 18157419 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrial (RA) pacing group
Number of subjects: 160
Study 18157419 — intervention group
Group type: COMPARATOR
Intervention: Non‐pacing (NP) group
Number of subjects: 160
Study 16736131 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose and tight blood pressure control policies
Number of subjects: 4320
Study 16736131 — intervention group
Group type: COMPARATOR
Intervention: Glycaemia control (HbA(1c) <6.0%) and blood pressure control (SBP <130 mmHg)
Number of subjects: 4320
Study 16736131 — intervention group
Group type: COMPARATOR
Intervention: Glycaemia control (HbA(1c) > or =8%) and blood pressure control (SBP > or =150 mmHg)
Number of subjects: 4320
Study 16736131 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated mean HbA(1c) decrement
Number of subjects: 4320
Study 16736131 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated mean SBP decrement
Number of subjects: 4320
Study 12686922 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic eminoplasty
Number of subjects: 24
Study 12686922 — intervention group
Group type: COMPARATOR
Intervention: Conventional open eminectomy
Number of subjects: 24
Study 10898316 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood clot
Number of subjects: 100
Study 10898316 — intervention group
Group type: COMPARATOR
Intervention: Gelfoam
Number of subjects: 100
Study 9184881 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency portacaval shunt performed within 8 hr of initial contact (21 patients)
Number of subjects: 43
Study 9184881 — intervention group
Group type: COMPARATOR
Intervention: Emergency medical therapy (intravenous vasopressin and esophageal balloon tamponade) followed by elective portacaval shunt in survivors (22 patients)
Number of subjects: 43
Study 9184881 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency portacaval shunt
Number of subjects: 43
Study 9184881 — intervention group
Group type: COMPARATOR
Intervention: Emergency medical therapy
Number of subjects: 43
Study 9184881 — intervention group
Group type: COMPARATOR
Intervention: Emergency medical therapy and elective shunt
Number of subjects: 43
Study 7682261 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 60-80 mg/kg alone (Group A)
Number of subjects: 293
Study 7682261 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus intravenous gamma globulin (IVGG) 400 mg/kg for 5 days (Group B)
Number of subjects: 293
Study 7682261 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus a single dose of IVGG 2.0 gm/kg (Group C)
Number of subjects: 293
Study 3105568 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine
Number of subjects: 30
Study 3105568 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 30
Study 3105568 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 30
Study 28715141 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut consumption for 5 days
Number of subjects: 10
Study 28715141 — intervention group
Group type: COMPARATOR
Intervention: Placebo consumption for 5 days
Number of subjects: 10
Study 27198484 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (1 Hz, 90% resting motor threshold)
Number of subjects: 25
Study 27198484 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 25
Study 27198484 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 25
Study 24902402 — intervention group
Group type: EXPERIMENTAL
Intervention: ABR - 3x/day-1 minute toothbrushing
Number of subjects: 13
Study 24902402 — intervention group
Group type: EXPERIMENTAL
Intervention: ERO - 3x/day - 5 minutes extraoral immersion into regular Coca Cola
Number of subjects: 13
Study 24902402 — intervention group
Group type: COMPARATOR
Intervention: CONT - control (no challenge)
Number of subjects: 13
Study 24902402 — intervention group
Group type: EXPERIMENTAL
Intervention: ERO+ABR - erosive protocol followed by a 1-minute toothbrushing
Number of subjects: 13
Study 22551107 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP plus mitotane
Number of subjects: 304
Study 22551107 — intervention group
Group type: COMPARATOR
Intervention: Streptozocin plus mitotane
Number of subjects: 304
Study 22551107 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP plus mitotane (second-line therapy)
Number of subjects: 304
Study 22551107 — intervention group
Group type: COMPARATOR
Intervention: Streptozocin plus mitotane (second-line therapy)
Number of subjects: 304
Study 22551107 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP plus mitotane (first-line therapy, no second-line therapy)
Number of subjects: 304
Study 22551107 — intervention group
Group type: COMPARATOR
Intervention: Streptozocin plus mitotane (first-line therapy, no second-line therapy)
Number of subjects: 304
Study 20858746 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol, n‐butanol, or n‐hexanol (3‐s pulses, 9 pulses total)
Number of subjects: 0
Study 20858746 — intervention group
Group type: COMPARATOR
Intervention: Control (3‐s pulses of clean air interspersed)
Number of subjects: 0
Study 18245143 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of supervised exercise training
Number of subjects: 57
Study 18245143 — intervention group
Group type: COMPARATOR
Intervention: Weekly telephone support (control)
Number of subjects: 57
Study 16015276 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinegar (18 mmol acetic acid)
Number of subjects: 12
Study 16015276 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinegar (23 mmol acetic acid)
Number of subjects: 12
Study 16015276 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinegar (28 mmol acetic acid)
Number of subjects: 12
Study 16015276 — intervention group
Group type: EXPERIMENTAL
Intervention: Low and intermediate levels of vinegar
Number of subjects: 12
Study 16015276 — intervention group
Group type: COMPARATOR
Intervention: Reference meal (bread without vinegar)
Number of subjects: 12
Study 12885487 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg aspirin daily
Number of subjects: 1756
Study 12885487 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg aspirin daily
Number of subjects: 1756
Study 12885487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1756
Study 9890407 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg nicorandil
Number of subjects: 33
Study 9890407 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg nitroglycerin
Number of subjects: 33
Study 9890407 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional application of nicorandil after nitroglycerin
Number of subjects: 33
Study 8526698 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (80 mmol/d)
Number of subjects: 87
Study 8526698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 1804576 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg b.i.d. perorally)
Number of subjects: 8
Study 1804576 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 8
Study 1804576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6871129 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed pushing
Number of subjects: 76
Study 6871129 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 76
Study 31721666 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile polyacrylate wound dressing with activated carbon cloth
Number of subjects: 248
Study 31721666 — intervention group
Group type: COMPARATOR
Intervention: Hydrocellular foam dressing with silver
Number of subjects: 248
Study 26894591 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg (Group-2)
Number of subjects: 60
Study 26894591 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg (Group-4)
Number of subjects: 60
Study 26894591 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 16 mg/kg (Group-16)
Number of subjects: 60
Study 26894591 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (all groups)
Number of subjects: 60
Study 25946210 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial ablation (area A)
Number of subjects: 25
Study 25946210 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep rejuvenation (area B)
Number of subjects: 25